ConductScience.org, home

Paper21622864

IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Rα2.

Kasaian MT and 6 others. J Immunol, 2011. Cited by 54 papers, by iCite.

Cite this record

ConductScience Library. IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Rα2. Papers, record 21622864. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21622864

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Rα2.
PubMed
Journal
J Immunol
PubMed
Year
2011
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
54
iCite
Relative citation ratio, by iCite
1.41
iCite
Revised in PubMed
2011-06-21
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kasaian MTMarion T
2Raible DDonald
3Marquette KKimberly
4Cook TATimothy A
5Zhou SSimon
6Tan XYXiang-Yang
7Tchistiakova LLioudmila

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Interleukin-13Major topic
Interleukin-13 Receptor alpha2 SubunitMajor topic
IsoantibodiesMajor topic
Receptors, ScavengerMajor topic
Animals
Antibody-Dependent Cell Cytotoxicity
Dose-Response Relationship, Immunologic
Drug Delivery Systems
Extracellular Space
HT29 Cells
Humans
Macaca fascicularis
Mice
Mice, Inbred BALB C

Source PubMed

Download CSV of topics

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 54 citations.

PMIDTitleJournalYearIn PapersSource
42573974Context-dependent promotion of epithelial-mesenchymal transition by IL-13Rα2/STAT6 signaling in colorectal cancer.Mol Cell Biochem2026https://conductscience.org/library/papers/42573974PubMed
39258338
A model-based approach using GSK3772847, an anti-interleukin-33 receptor monoclonal antibody, as a showcase to predict SC administration PK and free target dynamics based on PK and total target measurements after IV administration.
CPT Pharmacometrics Syst Pharmacol2025https://conductscience.org/library/papers/39258338PubMed
38928038Comparative Analysis of Orthosteric and Allosteric GLP-1R Agonists' Effects on Insulin Secretion from Healthy, Diabetic, and Recovered INS-1E Pancreatic Beta Cells.Int J Mol Sci2024https://conductscience.org/library/papers/38928038PubMed
37554517Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Signaling Complex but Not the IL-13/IL-13Rα2 Complex.JID Innov2023https://conductscience.org/library/papers/37554517PubMed
37310643Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab.Dermatol Ther (Heidelb)2023https://conductscience.org/library/papers/37310643PubMed
36759378Best Practices in mAb and Soluble Target Assay Selection for Quantitative Modelling and Qualitative Interpretation.AAPS J2023https://conductscience.org/library/papers/36759378PubMed
36303796A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody Programs.Front Bioinform2021https://conductscience.org/library/papers/36303796PubMed
33559859Interleukin-31, a Potent Pruritus-Inducing Cytokine and Its Role in Inflammatory Disease and in the Tumor Microenvironment.Adv Exp Med Biol2021https://conductscience.org/library/papers/33559859PubMed
33459147Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors.MAbs2021https://conductscience.org/library/papers/33459147PubMed
32294982Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis.Viruses2020https://conductscience.org/library/papers/32294982PubMed
31866859The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma.Front Pharmacol2019https://conductscience.org/library/papers/31866859PubMed
31557987Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer.Antibodies (Basel)2016https://conductscience.org/library/papers/31557987PubMed
31509236The IL-13-OVOL1-FLG axis in atopic dermatitis.Immunology2019https://conductscience.org/library/papers/31509236PubMed
31284553Scratching Counteracts IL-13 Signaling by Upregulating the Decoy Receptor IL-13Rα2 in Keratinocytes.Int J Mol Sci2019https://conductscience.org/library/papers/31284553PubMed
30825336Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches.Exp Dermatol2019https://conductscience.org/library/papers/30825336PubMed
30233597Fra2 Overexpression in Mice Leads to Non-allergic Asthma Development in an IL-13 Dependent Manner.Front Immunol2018https://conductscience.org/library/papers/30233597PubMed
28455782RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study.Adv Ther2017https://conductscience.org/library/papers/28455782PubMed
27049478A mechanistic PK/PD model for two anti-IL13 antibodies explains the difference in total IL-13 accumulation observed in clinical studies.MAbs2016https://conductscience.org/library/papers/27049478PubMed
26132778IL-13 Stimulates Proliferation and Expression of Mucin and Immunomodulatory Genes in Cultured Conjunctival Goblet Cells.Invest Ophthalmol Vis Sci2015https://conductscience.org/library/papers/26132778PubMed
25614144A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients.Br J Clin Pharmacol2015https://conductscience.org/library/papers/25614144PubMed

See all 23 cited byDownload CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
IL133596Swiss-Prot's referenceshttps://conductscience.org/library/genes/3596NCBI Gene
IL13RA13597PubTator's text mininghttps://conductscience.org/library/genes/3597NCBI Gene
IL13RA23598PubTator's text mininghttps://conductscience.org/library/genes/3598NCBI Gene
IL4R3566PubTator's text mininghttps://conductscience.org/library/genes/3566NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/21622864

GET https://conductscience.org/api/papers/v1/21622864/cited_by?page=2